SCHEMBL5640950

SCHEMBL5640950

CCC[C@H](C(N)=O)[C@@H](CC1CCCC1)C(=O)N[C@@H]1C(=O)N(Cc2cccc(-c3ccc(Cl)cc3Cl)c2)c2ccccc2-c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 5/20 0.47
▸ PSEN2 P49810 5/20 0.47
▸ APH1B Q8WW43 5/20 0.47
▸ NCSTN Q92542 5/20 0.47
▸ APH1A Q96BI3 5/20 0.47
▸ PSENEN Q9NZ42 5/20 0.47
▸ APP P05067 10/20 0.43
▸ NOTCH1 P46531 3/20 0.38
▸ RBPJ Q06330 2/20 0.38
▸ OXTR P30559 1/20 0.38
▸ NOTCH3 Q9UM47 1/20 0.36
▸ XIAP P98170 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499925 1.00 PSEN1 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4493771 0.99 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4499476 0.97 PSEN1 (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5921870 0.96 PSEN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4487715 0.96 PSEN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4488978 0.95 NOTCH1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5645437 0.93 NOTCH1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4482439 0.93 NOTCH1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4483056 0.91 PSEN1 (0.51) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4498485 0.90 NOTCH1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304055-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-23 — — US disclosed
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264417-A1 Succinoylamino lactams as inhibitors of a-beta protein production BACE1, APH1A, APP PSEN1 7/4885PSEN2 9/4885APH1B 4/4885
US-20060258638-A1 Succinoylamino lactams as inhibitors of A-beta protein production BACE1, APH1A, APP PSEN1 7/4885PSEN2 9/4885APH1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback